Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES LAGERKRANTZ GROUP IN CONNECTION WITH ACQUISIITON OF LANDAUER NORDIC
Mandate

VINGE ADVISES LAGERKRANTZ GROUP IN CONNECTION WITH ACQUISIITON OF LANDAUER NORDIC

October 01, 2015

Vinge has advised Lagerkrantz Group in connection with the acquisition of Landauer Nordic from Landauer, Inc. Landauer Nordic develops and sells products and services for the measurement of radon. The company’s headquarters are situated in Uppsala and the company has a subsidiary in Chicago, USA. Landauer Nordic has an annual turnover of SEK 40 million with good profitability.

Vinge’s team consisted of partner Johan Winnerblad together with, among others, associates Filip Öhrner, Carl Sander, Evelina Tejle and Rebecka Weitzberg.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026